Monte Carlo simulation demonstrates effective dosing for CRE infections in patients with varying renal function, suggesting a safe treatment strategy.
Co-administration of CZA and aztreonam using renal-adjusted doses provides a practical and effective strategy for MBL-CRE infections. This approach ensures high joint PTA attainment while maintaining a low neurotoxicity risk across all renal function strata.
No takes yet. Share an insight, caveat, or question.
Hemapanpairoa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: